Accelerating data-driven medical research through a platform that can securely distribute and utilize medical data
NTT Life Science Corporation launches Japan Precision Medicine Platform^TM

Tokyo - April 15, 2024 - BC Platforms AG (BCP), Bio-Xcelerator K. K., NTT Corporation (NTT), NTT Life Sciences Corporation (NTT Life Sciences), and Prime Research Institute for Medical RWD, Inc. (PRiME-R,Inc) will promote the creation of next-generation medical research platforms through the secure distribution and utilization of medical data. NTT Life Sciences will begin offering the Japan Precision Medicine Platform¹ (JPP) today. In addition, we will start recruiting domestic and overseas pharmaceutical companies that want to utilize JPP for medical and pharmaceutical research and development.
　BCP has agreed to promote JPP and signed an exclusive contract in Japan to provide data utilization services and technologies with proven global experience for this project, including NTT Life Sciences, which is the core of the NTT Group's medical business.

President and CEO of NTT Life Science and President of PRiME-R Kouji Korekawa (left), BCP Chairman of the Board Laurent Samama (center), NTT Senior Vice President Akiko Kudo (right)

Medical expenses in Japan have been increasing each year, and in FY2020, they amounted to 42,719.3 billion yen, accounting for 32.3% of social security benefits². This is one of the major challenges that cannot be avoided to realize a sustainable society.

With the partnership announced in October 2023³, NTT Life Sciences has launched the Japan Precision Medicine Platform^TM, which enables researchers in Japan and abroad to efficiently promote research for next-generation medicine by utilizing BCP systems and know-how to realize a safe use environment for medical healthcare data.

This platform enables users to handle sensitive medical healthcare data in a secure and closed environment (the globally proven TRE⁴ environment) within the allowed limits without taking the data outside.

The BCP and the NTT Group aim to achieve significant healthcare structural reform and innovation by promoting the safe use of medical healthcare data and enhancing the quality and efficiency of medical care through their respective achievements and strengths.

"We are delighted that NTT Life Science will exclusively represent our technology in Japan. This powerful strategic partnership with NTT Group is a core element of our mission to be a leading real-world data (RWD)⁵, technology, and services provider," said BCP's Chairman of the Board, Laurent Samama. "By collaborating with one of the world's largest technology companies⁶, we boost our ability to scale, and maximize, the value of our capabilities, as we build the world's largest health data network."

"In the NTT Group's Medium-Term Management Strategy 'New value creation & Sustainability 2027 powered by IOWN' (announced in May 2023)⁷ we announced that we will promote new value creation through data-driven initiatives. The JPP is a concrete and major example of this initiative. We aim to create a market as soon as possible with BCP, which has a global track record in the medical field, a growing market and an investment field for NTT." said Akiko Kudo NTT SVP, Head of Alliance Department, Research and Development Market Strategy Division, Member of the Board.

"We are committed to making a difference in precision medicine by leveraging powerful data-driven insights. Our ambition is to transform the world's healthcare solutions, starting from Japan, which is already a powerhouse in medical research. 47 medical institutions have already utilized PRiME-R' s Cyber R series, led by CyberOncology^®. The Genovision Dock^®8 has been used in 59 medical institutions, and more than 80,000 customers have been tested. Using this strength, we will continue to promote JPP." said Kouji Korekawa, President and CEO of NTT Life Science and President of PRiME-R.

Strengths and roles of each company

○ BC Platforms AG

○ Bio-Xcelerator K. K.

○ NTT

○ NTT Life Sciences

○ PRiME-R

¹JPP
A platform that enables Japanese researchers to efficiently conduct research for next-generation medical care in Japan by developing medical data for Japanese medical institutions using BCP systems and know-how by the NTT Group (service provided by NTT Life Sciences).

²"2020 Overview of National Medical Expenses" November 30, 2022 Ministry of Health, Labour and Welfare
https://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/20/index.html

³Press Release Regarding the Conclusion of Partnership
October 3, 2023 press release
Collaboration for Creating New Value in the Medical Field through Data-Driven Technology
https://group.ntt/en/newsrelease/2023/10/03/231003a.html

⁴Trusted Research Environment (TRE)
A trusted research environment and computer resource that technically prevents the medical data from being exported

⁵Real World Data (RWD)
General term for medical data obtained in daily clinical practice. Data from electronic medical records, receipts, DPC (Diagnosis Procedure Combination), medical examination data, patient registry data, and wearable devices.

⁶NTT IR DAY 2023 (October 3, 2023)
https://group.ntt/en/ir/library/presentation/institutional/

⁷NTT Group Medium-Term Management Strategy "New value creation & Sustainability 2027 powered by IOWN"
https://group.ntt/en/ir/mgt/managementstrategy/

⁸Genovision Dock^®
https://service.ntt-lifescience.co.jp/rpts/anonymous/aboutdna

About BC Platforms AG

BC Platforms is a global leader in building data networks for the life sciences industry and providing versatile technology platforms for research and precision medicine, accelerating the translation of innovations into clinical practice. Founded in 1997 from a MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, as well as a presence in London, UK, Lund, Sweden, Paris and Toulouse, France and Boston, USA.

https://www.bcplatforms.com/
https://www.linkedin.com/company/bc-platforms/

^*Genovision Dock^® is a registered trademark of NTT Life Science Corporation.

^*CyberOncology^® is a registered trademark of Prime Research Institute for Medical RWD, Inc.

Introduction Results:

About Bio-Xcelerator K. K.

BC Platforms AG Partner in Japan (since January 2020)

http://www.bio-xcelerator.com

About NTT

NTT contributes to a sustainable society through the power of innovation. We are a leading global technology company providing services to consumers and businesses as a mobile operator, infrastructure, networks, applications, and consulting provider. Our offerings include digital business consulting, managed application services, workplace and cloud solutions, data center and edge computing, all supported by our deep global industry expertise. We are over $97B in revenue and 330,000 employees, with $3.6B in annual R&D investments. Our operations span across 80+ countries and regions, allowing us to serve clients in over 190 of them. We serve over 75% of Fortune Global 100 companies, thousands of other enterprise and government clients and millions of consumers.